Chardan Capital Keeps Their Buy Rating on Intellia Therapeutics (NTLA)


In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Intellia Therapeutics (NTLA), with a price target of $57.50. The company’s shares opened today at $14.60, close to its 52-week low of $11.03.

Amusa commented:

“We see the current optimizations of the in vivo editing program as a step in that direction. Over the course of 2018, Intellia has also advanced its ex vivo engineered T cell receptor (TCR) cell therapy program and plans to nominate an autologous WT1-targeted TCR candidate for acute myeloid leukemia by the end of 2019.”

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.8% and a 47.7% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Voyager Therapeutics Inc.

Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.50.

See today’s analyst top recommended stocks >>

Based on Intellia Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.7 million. In comparison, last year the company had a GAAP net loss of $23.96 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts